Opportunity Information: Apply for PAR 25 051
The Blueprint Neurotherapeutics Network (BPN) opportunity (PAR 25-051) is a National Institutes of Health (NIH) cooperative agreement designed to help neuroscience investigators push promising small molecule drug projects further down the pipeline, with the explicit goal of moving candidates toward the clinic for disorders of the nervous system. The program is built to bridge the gap between academic discovery and the specialized, resource-heavy development work required to reach an Investigational New Drug (IND) application and early human testing. While applicants keep control of the core scientific direction of their project, the structure of the award is meant to surround research teams with practical drug-development capabilities that are often hard to assemble within a single lab or institution.
A key feature of BPN is the division of responsibilities and support. Awardees remain responsible for all disease- or target-specific work that depends on their unique expertise and tools, such as developing or running specialized assays, using disease models, validating targets, and generating the mechanistic or translational evidence needed to justify advancement. NIH funding covers the activities conducted in the awardee's own laboratory. At the same time, awardees collaborate with NIH-supported consultants and can also tap into NIH contract research organizations (CROs) to carry out major development tasks. Those CRO-enabled capabilities include medicinal chemistry, pharmacokinetics, toxicology, formulation development, chemical synthesis (including Good Manufacturing Practices, or GMP, when needed), and Phase I clinical testing. In practice, this means an investigator does not need to build a full pharmaceutical development operation from scratch to access the kinds of studies regulators expect before and during first-in-human work.
The program is structured so projects can enter at different starting points depending on maturity. One pathway is entry at the Discovery stage, where the focus is on taking promising hits or early leads and optimizing them through medicinal chemistry, improving properties like potency, selectivity, metabolic stability, brain penetration when relevant, and overall developability, with the aim of producing a development-ready candidate. Another pathway is entry at the Development stage, where the project centers on advancing a single nominated development candidate through IND-enabling studies, including the required toxicology package, and then moving into Phase I clinical testing. The announcement also notes that some projects may begin at the Development stage and move through IND-enabling work and Phase I in a shorter timeframe, reflecting that some applicants may already have substantial preclinical progress.
Because this is a cooperative agreement (UG3/UH3; clinical trial optional), the NIH role is more hands-on than in a standard research grant, emphasizing active collaboration and milestone-driven progression. Although the specific milestones and transition criteria are not detailed in the provided text, the UG3/UH3 format generally implies an initial phase focused on achieving predefined objectives that, if met, supports transition to a later phase oriented toward more advanced development activities. The "clinical trial optional" component signals that Phase I clinical testing can be part of the project when appropriate, but it is not a mandatory requirement for every applicant, depending on the stage and aims proposed.
Intellectual property (IP) terms are also highlighted as a major incentive. Awardee institutions retain their own IP rights, and they also gain assignment of IP rights from BPN contractors for drug candidates developed through the program. This is important because it leaves the institution in control of patent prosecution and licensing negotiations, which can be decisive for attracting follow-on investment, forming partnerships, or moving a candidate into later-stage clinical development beyond Phase I.
Eligibility is broad and includes many organization types: state, county, city, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other eligible entities. The opportunity explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. (foreign) entities. That breadth reflects an intent to draw strong neuroscience and drug discovery projects from many settings, not just traditional research-intensive universities.
From the source data, the agency is NIH and the opportunity category is discretionary. The funding activity category is listed under education and health, and several CFDA numbers are associated with the program (93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.866, 93.867), reflecting the multi-institute nature of NIH neuroscience and translational programs. The original closing date provided is 2026-08-18, and the record creation date is 2024-09-25. The award ceiling and expected number of awards are not specified in the provided information.
Overall, BPN is essentially an NIH-supported translational engine for small molecule neurotherapeutics: investigators bring the disease expertise, target biology, and specialized models, while NIH helps supply the development infrastructure and experienced consultants needed to turn early chemical matter into an IND-ready candidate and, when feasible, into Phase I testing, all while allowing awardee institutions to retain and consolidate IP control over resulting drug candidates.Apply for PAR 25 051
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.866, 93.867.
- This funding opportunity was created on 2024-09-25.
- Applicants must submit their applications by 2026-08-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - Blueprint Neurotherapeutics Network (BPN) (PAR 25-051)
What is the Blueprint Neurotherapeutics Network (BPN) opportunity (PAR 25-051)?
BPN (PAR 25-051) is a National Institutes of Health (NIH) cooperative agreement designed to help neuroscience investigators advance promising small molecule drug projects further down the development pipeline, with the explicit goal of moving candidates toward the clinic for disorders of the nervous system.
What is the main goal of this program?
The program is intended to bridge the gap between academic discovery and the specialized development work typically needed to reach an Investigational New Drug (IND) application and early human testing. It aims to help teams move from early chemical matter to an IND-ready development candidate and, when feasible, into Phase I clinical testing.
What kinds of projects does BPN support?
Based on the information provided, BPN supports small molecule neurotherapeutics projects aimed at disorders of the nervous system, spanning from discovery-stage optimization through development-stage IND-enabling work and potentially Phase I clinical testing.
Is this a standard NIH research grant?
No. This is a cooperative agreement (UG3/UH3; clinical trial optional). Compared with a standard research grant, NIH has a more hands-on role, emphasizing active collaboration and milestone-driven progression.
What does it mean that this is a cooperative agreement (UG3/UH3)?
The UG3/UH3 format generally implies an initial phase focused on achieving predefined objectives and milestones (UG3) that, if met, supports transition to a later phase (UH3) oriented toward more advanced development activities. The specific milestones and transition criteria are not detailed in the provided information.
What does "clinical trial optional" mean for this opportunity?
"Clinical trial optional" indicates that Phase I clinical testing can be included in the project when appropriate, but it is not mandatory for every applicant. Whether clinical work is proposed depends on the stage and aims of the project.
At what stage can a project enter the BPN program?
Projects can enter at different starting points depending on maturity. The opportunity describes entry at a Discovery stage or entry at a Development stage.
What happens in the Discovery stage pathway?
The Discovery stage focuses on taking promising hits or early leads and optimizing them through medicinal chemistry. Goals include improving potency, selectivity, metabolic stability, brain penetration (when relevant), and overall developability, with the aim of producing a development-ready candidate.
What happens in the Development stage pathway?
The Development stage centers on advancing a single nominated development candidate through IND-enabling studies (including the required toxicology package) and then moving into Phase I clinical testing.
Can some projects move through Development stage activities faster than others?
Yes. The opportunity notes that some projects may begin at the Development stage and move through IND-enabling work and Phase I in a shorter timeframe, reflecting that some applicants may already have substantial preclinical progress.
What responsibilities remain with the awardee (the funded investigator/team)?
Awardees remain responsible for disease- or target-specific work that depends on their unique expertise and tools. Examples given include developing or running specialized assays, using disease models, validating targets, and generating mechanistic or translational evidence needed to justify advancement.
What types of work does NIH funding cover in the awardee's lab?
NIH funding covers activities conducted in the awardee's own laboratory, particularly the disease- or target-specific work described in the opportunity.
What additional support does BPN provide beyond the awardee's lab?
Awardees collaborate with NIH-supported consultants and can also use NIH contract research organizations (CROs) to carry out major development tasks that can be difficult to assemble within a single lab or institution.
What CRO-enabled capabilities are available through BPN?
The opportunity lists CRO-enabled capabilities including medicinal chemistry, pharmacokinetics, toxicology, formulation development, chemical synthesis (including Good Manufacturing Practices (GMP) when needed), and Phase I clinical testing.
Why is CRO access a key feature of the program?
Because many of the studies regulators expect before and during first-in-human work are specialized and resource-intensive. BPN is structured so investigators do not need to build a full pharmaceutical development operation from scratch to access these capabilities.
Who controls the core scientific direction of the project?
Applicants keep control of the core scientific direction of their project, while being surrounded by practical drug-development capabilities and supported collaboration structures.
How does BPN support movement toward an IND application?
BPN supports the progression of small molecule projects by combining awardee-led disease/target work with CRO-supported development activities like pharmacokinetics, toxicology, formulation, GMP synthesis (when needed), and other IND-enabling studies, with the aim of reaching IND readiness and potentially Phase I testing.
What are the intellectual property (IP) terms described for BPN?
Awardee institutions retain their own IP rights, and they also gain assignment of IP rights from BPN contractors for drug candidates developed through the program.
Why are the IP terms considered an incentive?
Because the institution remains in control of patent prosecution and licensing negotiations, which can be important for attracting follow-on investment, forming partnerships, or moving a candidate into later-stage clinical development beyond Phase I.
Which agency is offering this opportunity?
The agency is the National Institutes of Health (NIH).
What is the opportunity category?
The opportunity category is listed as discretionary.
What is the funding activity category listed for this opportunity?
The funding activity category is listed under education and health.
Are any CFDA numbers associated with this program?
Yes. The opportunity lists multiple CFDA numbers: 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.866, 93.867.
What does it imply that multiple CFDA numbers are listed?
Based on the text provided, it reflects the multi-institute nature of NIH neuroscience and translational programs connected to this opportunity.
Who is eligible to apply?
Eligibility is broad and includes many organization types, including state, county, city, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other eligible entities.
Are specific institution types explicitly called out as eligible?
Yes. The opportunity explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) entities.
Are non-U.S. (foreign) entities eligible?
Yes. The opportunity explicitly includes non-U.S. (foreign) entities among eligible applicants.
What is the closing date for this opportunity?
The original closing date provided is 2026-08-18.
When was the record created?
The record creation date is 2024-09-25.
Is the award ceiling listed?
No. The award ceiling is not specified in the provided information.
Is the expected number of awards listed?
No. The expected number of awards is not specified in the provided information.
Does the opportunity specify exact milestones or UG3-to-UH3 transition criteria?
No. While the program is described as milestone-driven and the UG3/UH3 structure implies predefined objectives for transition, the specific milestones and transition criteria are not detailed in the provided text.
What is the practical value proposition of BPN for academic or non-industry teams?
BPN is described as an NIH-supported translational engine: investigators bring disease expertise, target biology, and specialized models, while NIH helps supply development infrastructure, experienced consultants, and access to CRO-performed work needed to turn early chemical matter into an IND-ready candidate and, when feasible, into Phase I testing.
Browse more opportunities from the same category: Education, Health
Next opportunity: FY25 IIJA/IRA Bureau of Land Management Idaho (ID) Youth Conservation Corps
Previous opportunity: Training and Technical Assistance to Improve Water Quality and Enable Small Public Water Systems to Provide Safe Drinking Water
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 051
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 051) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center (U24 Clinical Trials Not Allowed) Apply for RFA CA 24 036 Funding Number: RFA CA 24 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed) Apply for RFA DA 26 010 Funding Number: RFA DA 26 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed) Apply for RFA DA 26 009 Funding Number: RFA DA 26 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA CA 25 013 Funding Number: RFA CA 25 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) Apply for PA 25 080 Funding Number: PA 25 080 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required) Apply for RFA CA 25 010 Funding Number: RFA CA 25 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required) Apply for RFA CA 25 009 Funding Number: RFA CA 25 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required) Apply for RFA CA 24 031 Funding Number: RFA CA 24 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed) Apply for RFA CA 24 035 Funding Number: RFA CA 24 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: $850,000 |
| Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Center (U24 Clinical Trial Not Allowed) Apply for RFA CA 24 034 Funding Number: RFA CA 24 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $8,140,000 |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) Apply for PA 25 123 Funding Number: PA 25 123 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) Apply for PA 25 121 Funding Number: PA 25 121 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required) Apply for RFA CA 24 030 Funding Number: RFA CA 24 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) Apply for PAR 24 304 Funding Number: PAR 24 304 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed) Apply for RFA CA 24 033 Funding Number: RFA CA 24 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,700,000 |
| Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required) Apply for RFA CA 24 032 Funding Number: RFA CA 24 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) Apply for PAR 25 098 Funding Number: PAR 25 098 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) Apply for PAR 25 075 Funding Number: PAR 25 075 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) Apply for RFA DA 25 070 Funding Number: RFA DA 25 070 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) Apply for RFA DA 25 072 Funding Number: RFA DA 25 072 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 051", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.